Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction

被引：0
|
作者：
Giovanni Battista Bolla
Antonella Fedele
Andrea Faggiano
Carla Sala
Gloria Santangelo
Stefano Carugo
机构：
[1] University of Milan and Fondazione IRCCS Ca’ GrandaOspedale Maggiore Policlinico,Department of Clinical Sciences and Community Health
[2] Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,Cardiology Unit, Internal Medicine Department
[3] University of Milan,Division of Cardiology, Department of Health Sciences, San Paolo Hospital
来源：
BMC Cardiovascular Disorders | / 22卷
关键词：
Heart failure; Sacubitril/Valsartan; Biomarkers; Fibrosis; Left ventricular ejection fraction;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan
    Rex C. Liu
    American Journal of Cardiovascular Drugs, 2018, 18 : 473 - 482
  • [32] Left ventricular ejection fraction recovery in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan.
    Diez Villanueva, P.
    De la Cuerda, F.
    Vicent, L.
    Esteban-Fernandez, A.
    Gomez-Bueno, M.
    De Juan, J.
    Iniesta, A. M.
    Ayesta, A.
    Rojas, A.
    Bover, R.
    Iglesias, D.
    Garcia Aguado, M.
    Perea Egido, J. A.
    Salamanca, J.
    Martinez-Selles, M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 206 - 207
  • [33] Sacubitril/Valsartan in the primary treatment of heart failure with reduced ejection fraction (HFrEF)
    Nowak, Bernd
    Geiss, Ernst
    Boehm, Michael
    Weil, Joachim
    Boer, Jana
    KARDIOLOGIE, 2023, : 44 - 48
  • [34] Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction
    Raschi, Emanuel
    Diemberger, Igor
    Sabatino, Mario
    Poluzzi, Elisabetta
    De Ponti, Fabrizio
    Potena, Luciano
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (03) : 303 - 320
  • [35] Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
    Khan, Muhammad Nauman
    Soomro, Najia Aslam
    Naseeb, Khalid
    Bhatti, Usman Hanif
    Rauf, Rubina
    Balouch, Iram Jehan
    Moazzam, Ali
    Bashir, Sonia
    Ashraf, Tariq
    Karim, Musa
    BMC CARDIOVASCULAR DISORDERS, 2023, 23 (01)
  • [36] Sacubitril/valsartan reduces ventrucular arrhythmias in heart failure with reduced ejection fraction
    Lamaida, Norman
    Torella, Giorgio
    Cerciello, Antonio
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0N) : N26 - N26
  • [37] Current evidence of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
    Abumayyaleh, Mohammad
    El-Battrawy, Ibrahim
    Behnes, Michael
    Borggrefe, Martin
    Akin, Ibrahim
    FUTURE CARDIOLOGY, 2020, 16 (04) : 227 - 236
  • [38] Sacubitril/valsartan and low blood pressure in heart failure with reduced ejection fraction
    Bruno, Rosa Maria
    Taddei, Stefano
    EUROPEAN HEART JOURNAL, 2017, 38 (15) : 1144 - 1146
  • [39] Targeting sacubitril/valsartan for heart failure with mildly reduced or preserved ejection fraction
    Greene, Stephen J.
    Fonarow, Gregg C.
    EUROPEAN HEART JOURNAL, 2023, 44 (31) : 2994 - 2997
  • [40] Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
    Muhammad Nauman Khan
    Najia Aslam Soomro
    Khalid Naseeb
    Usman Hanif Bhatti
    Rubina Rauf
    Iram Jehan Balouch
    Ali Moazzam
    Sonia Bashir
    Tariq Ashraf
    Musa Karim
    BMC Cardiovascular Disorders, 23
12345